- Home
- ALV
ALV
Autoliv Inc.
as 02-21-2025 4:00pm EST
Autoliv is the global leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
| Founded: | 1953 | Country: | Sweden |
| Employees: | N/A | City: | OGDEN |
| Market Cap: | 7.9B | IPO Year: | 1997 |
| Target Price: | $119.00 | AVG Volume (30 days): | 884.4K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 8.04 | EPS Growth: | 40.56 |
| 52 Week Low/High: | $89.51 - $129.38 | Next Earning Date: | 01-31-2025 |
| Revenue: | $10,390,000,000 | Revenue Growth: | -0.81% |
| Revenue Growth (this year): | 0.88% | Revenue Growth (next year): | 4.69% |
Latest Autoliv Inc. News
ALV Breaking Stock News: Dive into ALV Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Stellantis' Lawsuit Over Cartel Activity in UK Dismissed by Competition Appeal Tribunal
Reuters
a day ago
Stellantis' $807 million UK lawsuit over airbag, seatbelt cartels dismissed
PR Newswire
a day ago
Autoliv Declares Quarterly Dividend
PR Newswire
2 days ago
Autoliv publishes its Annual and Sustainability Report for 2024
Argus Research
4 days ago
ALV: Raising target price to $106.00
Simply Wall St.
6 days ago
Autoliv's (NYSE:ALV) 8.2% CAGR outpaced the company's earnings growth over the same five-year period
Zacks
9 days ago
Autoliv Plummets 15% in a Year: Here's Why the Stock is a Sell
Argus Research
18 days ago
ALV: Lowering target price to $99.00
Compare ALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALV Autoliv Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.